Skip to main content
PMC home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1991 Feb;84(2):63–65. doi: 10.1177/014107689108400201

Prospects for the treatment of multiple sclerosis.

R A Hughes
PMCID: PMC1293085  PMID: 1847975

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acha-Orbea H., Mitchell D. J., Timmermann L., Wraith D. C., Tausch G. S., Waldor M. K., Zamvil S. S., McDevitt H. O., Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988 Jul 15;54(2):263–273. doi: 10.1016/0092-8674(88)90558-2. [DOI] [PubMed] [Google Scholar]
  2. Bever C. T., Jr, Leslie J., Camenga D. L., Panitch H. S., Johnson K. P. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol. 1990 Apr;27(4):421–427. doi: 10.1002/ana.410270411. [DOI] [PubMed] [Google Scholar]
  3. Brown J. R., Beebe G. W., Kurtzke J. F., Loewenson R. B., Silberberg D. H., Tourtellotte W. W. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology. 1979 Sep;29(9 Pt 2):3–23. doi: 10.1212/wnl.29.9_part_2.3. [DOI] [PubMed] [Google Scholar]
  4. Cook S. D., Devereux C., Troiano R., Hafstein M. P., Zito G., Hernandez E., Lavenhar M., Vidaver R., Dowling P. C. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet. 1986 Jun 21;1(8495):1405–1409. doi: 10.1016/s0140-6736(86)91554-0. [DOI] [PubMed] [Google Scholar]
  5. Cook S. D., Troiano R., Zito G., Rohowsky-Kochan R., Sheffit C., Dowling P. C., Devereux C. K. Deaths after total lymphoid irradiation for multiple sclerosis. Lancet. 1989 Jul 29;2(8657):277–278. doi: 10.1016/s0140-6736(89)90463-7. [DOI] [PubMed] [Google Scholar]
  6. Hartung H. P., Schäfer B., Heininger K., Stoll G., Toyka K. V. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, biochemical and morphological observations. Brain. 1988 Oct;111(Pt 5):1039–1059. doi: 10.1093/brain/111.5.1039. [DOI] [PubMed] [Google Scholar]
  7. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  8. Heber-Katz E., Acha-Orbea H. The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today. 1989 May;10(5):164–169. doi: 10.1016/0167-5699(89)90174-6. [DOI] [PubMed] [Google Scholar]
  9. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  10. McKhann G. M. The trials of clinical trials. Arch Neurol. 1989 Jun;46(6):611–614. doi: 10.1001/archneur.1989.00520420029020. [DOI] [PubMed] [Google Scholar]
  11. Milligan N. M., Newcombe R., Compston D. A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. doi: 10.1136/jnnp.50.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Noseworthy J. H., Vandervoort M. K., Wong C. J., Ebers G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 Jun;40(6):971–975. doi: 10.1212/wnl.40.6.971. [DOI] [PubMed] [Google Scholar]
  13. Ormerod I. E., Miller D. H., McDonald W. I., du Boulay E. P., Rudge P., Kendall B. E., Moseley I. F., Johnson G., Tofts P. S., Halliday A. M. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987 Dec;110(Pt 6):1579–1616. doi: 10.1093/brain/110.6.1579. [DOI] [PubMed] [Google Scholar]
  14. Penn R. D., Savoy S. M., Corcos D., Latash M., Gottlieb G., Parke B., Kroin J. S. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989 Jun 8;320(23):1517–1521. doi: 10.1056/NEJM198906083202303. [DOI] [PubMed] [Google Scholar]
  15. Rose A. S., Kuzma J. W., Kurtzke J. F., Namerow N. S., Sibley W. A., Tourtellotte W. W. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology. 1970 May;20(5):1–59. doi: 10.1212/wnl.20.5_part_2.1. [DOI] [PubMed] [Google Scholar]
  16. Rudge P., Koetsier J. C., Mertin J., Mispelblom Beyer J. O., Van Walbeek H. K., Clifford Jones R., Harrison J., Robinson K., Mellein B., Poole T. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989 May;52(5):559–565. doi: 10.1136/jnnp.52.5.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Soulillou J. P., Cantarovich D., Le Mauff B., Giral M., Robillard N., Hourmant M., Hirn M., Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990 Apr 26;322(17):1175–1182. doi: 10.1056/NEJM199004263221702. [DOI] [PubMed] [Google Scholar]
  18. Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. doi: 10.1212/wnl.39.7.969. [DOI] [PubMed] [Google Scholar]
  19. Urban J. L., Horvath S. J., Hood L. Autoimmune T cells: immune recognition of normal and variant peptide epitopes and peptide-based therapy. Cell. 1989 Oct 20;59(2):257–271. doi: 10.1016/0092-8674(89)90288-2. [DOI] [PubMed] [Google Scholar]
  20. Willoughby E. W., Paty D. W. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988 Nov;38(11):1793–1798. doi: 10.1212/wnl.38.11.1793. [DOI] [PubMed] [Google Scholar]
  21. Wraith D. C., Smilek D. E., Mitchell D. J., Steinman L., McDevitt H. O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 1989 Oct 20;59(2):247–255. doi: 10.1016/0092-8674(89)90287-0. [DOI] [PubMed] [Google Scholar]
  22. Wynn D. R., Rodriguez M., O'Fallon W. M., Kurland L. T. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology. 1990 May;40(5):780–786. doi: 10.1212/wnl.40.5.780. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES